Grand Pharmaceutical Group Limited (0512) Stock Forecast & Price Target

Compare

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0512 Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Grand

Pharmaceutical Group Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0512 Stock 12 Month Forecast

Average Price Target

HK$11.88

▲(45.05% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Grand Pharmaceutical Group Limited in the last 3 months. The average price target is HK$11.88 with a high forecast of HK$11.88 and a low forecast of HK$11.88. The average price target represents a 45.05% change from the last price of HK$8.19.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"HK$3","12":"HK$12","5.25":"HK$5.25","7.5":"HK$7.5","9.75":"HK$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$11.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$11.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$11.88</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.25,7.5,9.75,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2023","6":"Oct<br/>2024","9":"Jun<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.24,8.52,8.8,9.08,9.36,9.64,9.92,10.200000000000001,10.48,10.760000000000002,11.040000000000001,11.32,11.600000000000001,{"y":11.88,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.24,8.52,8.8,9.08,9.36,9.64,9.92,10.200000000000001,10.48,10.760000000000002,11.040000000000001,11.32,11.600000000000001,{"y":11.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.24,8.52,8.8,9.08,9.36,9.64,9.92,10.200000000000001,10.48,10.760000000000002,11.040000000000001,11.32,11.600000000000001,{"y":11.88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.57,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.57,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.57,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.57,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.57,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.57,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$11.88

Average Price TargetHK$11.88

Lowest Price TargetHK$11.88

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Guoyuan Securities (HK)

Not Ranked

Guoyuan Securities (HK)

HK$11.88

Buy

45.05%

Upside

Reiterated

12/15/25

Grand Pharmaceutical Group Limited (0512) Gets a Buy from Guoyuan Securities (HK)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$13

Buy

58.73%

Upside

Reiterated

09/02/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$11.7

Buy

42.86%

Upside

Reiterated

08/23/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$12

Buy

46.52%

Upside

Reiterated

08/21/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$13.07

Buy

59.58%

Upside

Reiterated

08/13/25

Unknown Analyst

GuoSen

Not Ranked

GuoSen

HK$11.03

Buy

34.68%

Upside

Reiterated

06/13/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$10.15

Buy

23.93%

Upside

Reiterated

05/20/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Guoyuan Securities (HK)

Not Ranked

Guoyuan Securities (HK)

HK$11.88

Buy

45.05%

Upside

Reiterated

12/15/25

Grand Pharmaceutical Group Limited (0512) Gets a Buy from Guoyuan Securities (HK)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$13

Buy

58.73%

Upside

Reiterated

09/02/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$11.7

Buy

42.86%

Upside

Reiterated

08/23/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$12

Buy

46.52%

Upside

Reiterated

08/21/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$13.07

Buy

59.58%

Upside

Reiterated

08/13/25

Unknown Analyst

GuoSen

Not Ranked

GuoSen

HK$11.03

Buy

34.68%

Upside

Reiterated

06/13/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$10.15

Buy

23.93%

Upside

Reiterated

05/20/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Grand Pharmaceutical Group Limited

1 Month

xxx

Success Rate

1/5 ratings generated profit

Average Return

-0.44%

upgraded a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 20.00% of your transactions generating a profit, with an average return of -0.44% per trade.

3 Months

xxx

Success Rate

1/5 ratings generated profit

Average Return

-3.98%

upgraded a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 20.00% of your transactions generating a profit, with an average return of -3.98% per trade.

1 Year

Bryce GeneronTR | OpenAI - 4o

Success Rate

1/5 ratings generated profit

Average Return

-4.00%

upgraded a buy rating 3 months ago

Copying Bryce Generon's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -4.00% per trade.

2 Years

xxx

Success Rate

1/5 ratings generated profit

Average Return

-4.00%

upgraded a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -4.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0512 Analyst Recommendation Trends

Rating

May 25

Jun 25

Aug 25

Sep 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0512 has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0512 average Analyst price target in the past 3 months is 11.88.

Each month's total comprises the sum of three months' worth of ratings.

0512 Financial Forecast

0512 Earnings Forecast

The previous quarter’s earnings for 0512 were HK$0.33.

0512 Sales Forecast

The previous quarter’s earnings for 0512 were HK$6.11B.

0512 Stock Forecast FAQ

What is HK:0512’s average 12-month price target, according to analysts?

Based on analyst ratings, Grand Pharmaceutical Group Limited’s 12-month average price target is 11.88.

What is HK:0512’s upside potential, based on the analysts’ average price target?

Grand Pharmaceutical Group Limited has 45.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Grand Pharmaceutical Group Limited a Buy, Sell or Hold?

Grand Pharmaceutical Group Limited has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Grand Pharmaceutical Group Limited’s share price target?

The average share price target for Grand Pharmaceutical Group Limited is 11.88. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$11.88 ,and the lowest forecast is HK$11.88. The average share price target represents 45.05% Increase from the current price of HK$8.19.

What do analysts say about Grand Pharmaceutical Group Limited?

Grand Pharmaceutical Group Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Grand Pharmaceutical Group Limited?

To buy shares of HK:0512, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Grand Pharmaceutical Group Limited (0512) Stock Forecast & Price Target

0512 Analyst Ratings

0512 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Grand Pharmaceutical Group Limited

0512 Analyst Recommendation Trends

0512 Financial Forecast

0512 Earnings Forecast

0512 Sales Forecast

0512 Stock Forecast FAQ

Detailed List of Analyst Forecasts